title: [Prostate cancer and chemotherapy: standards care and perspectives].
abstract: Docetaxel is a reference treatment of metastatic prostate cancer castration-resistant. Until now, the different associations were studied without benefit when compared to docetaxel as monotherapy. Cabazitaxel showed efficacy in second-line in patients with progressive disease during or after docetaxel chemotherapy. Other molecules are being evaluated in second-line post-docetaxel. Abiraterone acetate is an alternative treatment to cabazitaxel in metastatic second-line resistant to castration. Predictive factors to choice treatment must be evaluated and proposed to personalize treatment in the future. Docetaxel activity was also studied in early stage of prostate cancer and seems to be promising. A cabazitaxel activity in early stage of cancer is also being evaluated.
authors.affiliation: Hôpital européen Georges-Pompidou, département de cancérologie médicale, 20, rue Leblanc, 75015 Paris, France. yacine.hadjarab@wanadoo.fr
authors.forename: Yacine
authors.initials: Y
authors.lastname: Hadjarab
authors.forename: Stéphane
authors.initials: S
authors.lastname: Oudard
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents